Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Refractory CLL
NCT01051115Phase 2Unknown
- Sponsor
- University of Amsterdam
- Start
- Oct 2008
- Primary completion
- Jan 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic lymphocytic leukemia (CLL), sponsored by University of Amsterdam. Primary endpoint: Clinical response rate and quality (CR, PR) at 32 weeks. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01051115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051115.